Related Experiment Video
Updated: May 22, 2026
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease
O Hussein1, J Zidan, K Abu Jabal
1Internal Medicine Department A, Ziv Medical Center, Safed 13100, Israel.
Abstract:
Objective. The objective of the present study is to investigate the effect of rosiglitazone, metformin, ezetimibe, and valsartan (alone or in combinations) on paraoxonase (PON) activity and PON-mRNA expression in nonalcoholic fatty liver disease (NAFLD). Methods. 54 Male Sprague-Dawley rats were divided to 9 groups: chow diet group (15 weeks); methionine-choline-deficient diet (MCDD) group (15 weeks); MCDD-treated groups for the last 6 weeks with either metformin (M), rosiglitazone (R), metformin plus rosiglitazone (M+R), ezetimibe (E), valsartan (V), or a combination of R+M+V or of R+M+V+E for a total period of 15 weeks. Results. PON activities in serum and liver were decreased in MCDD rats. PON activity in serum increased significantly in all treatment groups. PON activity in liver was also increased significantly, except only in groups R, E, V, R+M+V, and R+M+V+E. Liver PON3 mRNA expression increased significantly in groups R+M, E, V, R+M+V, and R+M+V+E whereas liver PON2 mRNA expression increased significantly in MCDD, R+M, E, V, R+M+V, and R+M+V+E. Conclusions. PON activities in serum and liver were decreased in NAFLD. Treatment with insulin sensitizers, ezetimibe, and valsartan increased PON activity and reduced oxidative stress both in serum and liver.
Insights
Treatments for nonalcoholic fatty liver disease (NAFLD) involving insulin sensitizers, ezetimibe, and valsartan effectively increased paraoxonase (PON) activity in serum and liver, reducing oxidative stress.
Area of Science:
- Biochemistry
- Pharmacology
- Hepatology
Background:
- Nonalcoholic fatty liver disease (NAFLD) is associated with decreased paraoxonase (PON) activity.
- PON is an enzyme crucial for antioxidant defense and lipid metabolism.
Purpose of the Study:
- To investigate the effects of rosiglitazone, metformin, ezetimibe, and valsartan on PON activity and PON-mRNA expression in a rat model of NAFLD.
- To evaluate the impact of these drugs, alone and in combination, on oxidative stress markers in NAFLD.
Main Methods:
- Male Sprague-Dawley rats were fed a methionine-choline-deficient diet (MCDD) to induce NAFLD.
- Rats received treatments including rosiglitazone, metformin, ezetimibe, and valsartan for the final 6 weeks of a 15-week study period.
- Paraoxonase (PON) activity in serum and liver, and PON2/PON3 mRNA expression in the liver were measured.
Main Results:
- MCDD significantly decreased serum and liver PON activity.
- All tested drug treatments significantly increased serum PON activity.
- Liver PON activity increased in most treatment groups, with notable exceptions.
- Specific PON mRNA expressions (PON2 and PON3) showed varied significant increases across different treatment groups.
Conclusions:
- NAFLD is characterized by reduced PON activity in both serum and liver.
- Treatment with insulin sensitizers (rosiglitazone, metformin), ezetimibe, and valsartan effectively restored PON activity.
- These therapeutic interventions demonstrate potential in mitigating oxidative stress associated with NAFLD.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:29Pharmacogenomics: Identification of New Drug Targets
01:08Allosteric Regulation